Los Angeles Capital Management LLC Lowers Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Los Angeles Capital Management LLC decreased its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 67.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,172 shares of the biotechnology company’s stock after selling 24,674 shares during the period. Los Angeles Capital Management LLC’s holdings in Ironwood Pharmaceuticals were worth $50,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Robeco Institutional Asset Management B.V. lifted its stake in Ironwood Pharmaceuticals by 1,293.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 380,960 shares of the biotechnology company’s stock valued at $1,570,000 after acquiring an additional 353,624 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 50.1% in the third quarter. Harbor Capital Advisors Inc. now owns 168,071 shares of the biotechnology company’s stock valued at $692,000 after purchasing an additional 56,097 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Ironwood Pharmaceuticals by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 30,723 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 12,047 shares in the last quarter. Ballentine Partners LLC purchased a new position in Ironwood Pharmaceuticals during the third quarter worth about $89,000. Finally, Legacy Capital Group California Inc. bought a new stake in Ironwood Pharmaceuticals in the 3rd quarter worth about $59,000.

Ironwood Pharmaceuticals Stock Down 4.5 %

NASDAQ IRWD opened at $4.02 on Tuesday. The company has a market cap of $642.15 million, a PE ratio of -134.00 and a beta of 0.47. The firm’s 50-day simple moving average is $4.27 and its two-hundred day simple moving average is $5.45. Ironwood Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. During the same period last year, the business posted $0.12 earnings per share. The firm’s quarterly revenue was down 19.4% on a year-over-year basis. As a group, equities research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on IRWD shares. Wells Fargo & Company dropped their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Craig Hallum reduced their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Finally, Leerink Partners initiated coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a “market perform” rating and a $5.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.